Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Sponsor: Eastern Virginia Medical School
This PHASE2 trial investigates Recurrent Respiratory Papillomatosis and is currently completed. Eastern Virginia Medical School leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Virginia Medical School
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Northwell Health
- Sanford Health
- University of Alabama at Birmingham
- University of California, San Francisco
- University of Iowa
- Vanderbilt University
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Birmingham, United States
- • Iowa City, United States
- • Nashville, United States
- • New Hyde Park, United States
- • Norfolk, United States
- • San Francisco, United States
- • Sioux Falls, United States